{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:53Z","timestamp":1787028533170,"version":"build-2736575974"},"reference-count":48,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Foundation of Korea","award":["RS-2023-00219399"],"award-info":[{"award-number":["RS-2023-00219399"]}]},{"name":"National Research Foundation of Korea","award":["RS-2023-00274727"],"award-info":[{"award-number":["RS-2023-00274727"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>BCR-ABL tyrosine kinase inhibitors are commonly employed for the treatment of chronic myeloid leukemia, yet their impact on human malignant melanoma remains uncertain. In this study, we delved into the underlying mechanisms of specific BCR-ABL tyrosine kinase inhibitors (imatinib, nilotinib, ZM-306416, and AT-9283) in human melanoma A375P cells. We first evaluated the influence of these inhibitors on cell growth using cell proliferation and wound-healing assays. Subsequently, we scrutinized cell cycle regulation in drug-treated A375P cells using flow cytometry and Western blot assays. Notably, imatinib, nilotinib, ZM-306416, and AT-9283 significantly reduced cell proliferation and migration in A375P cells. In particular, nilotinib and AT-9283 impeded the G1\/S transition of the cell cycle by down-regulating cell cycle-associated proteins, including cyclin E, cyclin A, and CDK2. Moreover, these inhibitors reduced RB phosphorylation, subsequently inhibiting E2F transcriptional activity. Consequently, the expression of the E2F target genes (CCNA2, CCNE1, POLA1, and TK-1) was markedly suppressed in nilotinib and AT9283-treated A375P cells. In summary, our findings suggest that BCR-ABL tyrosine kinase inhibitors may regulate the G1-to-S transition in human melanoma A375P cells by modulating the RB-E2F complex.<\/jats:p>","DOI":"10.3390\/ijms25052956","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T05:31:12Z","timestamp":1709530272000},"page":"2956","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Regulation of Cell Cycle Progression through RB Phosphorylation by Nilotinib and AT-9283 in Human Melanoma A375P Cells"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1862-464X","authenticated-orcid":false,"given":"Trang Minh","family":"Pham","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Convergence Medical Science, Institute of Medical Sciences, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-6541","authenticated-orcid":false,"given":"Mahmoud","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Convergence Medical Science, Institute of Medical Sciences, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4619-6558","authenticated-orcid":false,"given":"Trang Huyen","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Convergence Medical Science, Institute of Medical Sciences, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7106-0578","authenticated-orcid":false,"given":"Md Entaz","family":"Bahar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Convergence Medical Science, Institute of Medical Sciences, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2051-504X","authenticated-orcid":false,"given":"Jin Seok","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Convergence Medical Science, Institute of Medical Sciences, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizi Firman","family":"Maulidi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Convergence Medical Science, Institute of Medical Sciences, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4128-0372","authenticated-orcid":false,"given":"Quang Nhat","family":"Ngo","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Convergence Medical Science, Institute of Medical Sciences, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-8257","authenticated-orcid":false,"given":"Deok Ryong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Convergence Medical Science, Institute of Medical Sciences, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3389\/fonc.2019.00853","article-title":"Cinobufagin Induces Cell Cycle Arrest at the G2\/M Phase and Promotes Apoptosis in Malignant Melanoma Cells","volume":"9","author":"Pan","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_2","first-page":"212242","article-title":"Metastatic melanoma\u2014A review of current and future drugs","volume":"2012","author":"Velho","year":"2012","journal-title":"Drugs Context"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5826\/dpc.0702a01","article-title":"Epidemiological trends in skin cancer What Does the Future Hold","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_4","first-page":"10","article-title":"Melanoma Pathology","volume":"Volume 1012","author":"Howe","year":"2016","journal-title":"Melanoma"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.suc.2014.07.002","article-title":"Principles of surgical treatment of malignant melanoma","volume":"94","author":"Kimbrough","year":"2014","journal-title":"Surg. Clin. North Am."},{"key":"ref_6","first-page":"19","article-title":"Chemotherapy Resistance Mechanisms in Advanced Skin Cancer","volume":"11","author":"Kalal","year":"2017","journal-title":"Oncol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Janostiak, R., Torres-Sanchez, A., Posas, F., and de Nadal, E. (2022). Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies. Cancers, 14.","DOI":"10.3390\/cancers14051265"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1038\/sj.onc.1209615","article-title":"RB and cell cycle progression","volume":"25","author":"Giacinti","year":"2006","journal-title":"Oncogene"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.cr.7290031","article-title":"Regulation of the G1 phase of the mammalian cell cycle","volume":"10","author":"Donjerkovic","year":"2000","journal-title":"Cell Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.molcel.2020.08.020","article-title":"Integrating Old and New Paradigms of G1\/S Control","volume":"80","author":"Rubin","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrm3629","article-title":"Control of cell cycle transcription during G1 and S phases","volume":"14","author":"Bertoli","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: P53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000140633","article-title":"BCR-ABL in chronic myelogenous leukemia\u2014How does it work?","volume":"119","author":"Goldman","year":"2008","journal-title":"Acta Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1002\/pmic.200600109","article-title":"Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells","volume":"6","author":"Liang","year":"2006","journal-title":"Proteomics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1750-9378-8-23","article-title":"Bcr-Abl tyrosine kinase inhibitors- current status","volume":"8","author":"Mughal","year":"2013","journal-title":"Infect. Agents Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.3816\/CLM.2008.s.003","article-title":"Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"8","author":"Kantarjian","year":"2008","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01630378","article-title":"The minute chromosome (Phl) in chronic granulocytic leukemia","volume":"8","author":"Nowell","year":"1962","journal-title":"Blut"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"key":"ref_21","first-page":"1958","article-title":"The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X","volume":"6","author":"Oetzel","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells","volume":"90","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/database\/baab048","article-title":"LINPS: A database for cancer-cell-specific perturbations of biological networks","volume":"2021","author":"Ahmed","year":"2021","journal-title":"Database"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2741\/4090","article-title":"Platelet-derived growth factor signaling in mesenchymal cells","volume":"18","author":"Donovan","year":"2013","journal-title":"Front. Biosci. Landmark Ed."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/1535-7163.MCT-08-0889","article-title":"Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor","volume":"8","author":"Abouantoun","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_27","first-page":"238","article-title":"Determination of propranolol in human plasma by reversed phase high performance liquid chromatography","volume":"22","author":"Yuan","year":"1987","journal-title":"Acta Pharm. Sin."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4149\/neo_2021_201126N1282","article-title":"Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer","volume":"68","author":"Wang","year":"2021","journal-title":"Neoplasma"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Leal-Esteban, L.C., and Fajas, L. (2020). Cell cycle regulators in cancer cell metabolism. Biochim. Biophys. Acta. Mol. Basis Dis., 1866.","DOI":"10.1016\/j.bbadis.2020.165715"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10699","DOI":"10.1073\/pnas.94.20.10699","article-title":"Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4\/6 complexes results in active pRb","volume":"94","author":"Ezhevsky","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1038\/onc.2008.74","article-title":"Cyclin A\/cdk2 coordinates centrosomal and nuclear mitotic events","volume":"27","author":"Oakes","year":"2008","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-019-00337-6","article-title":"CDK4\/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib","volume":"33","author":"Eggersmann","year":"2019","journal-title":"BioDrugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"693104","DOI":"10.3389\/fonc.2021.693104","article-title":"Clinical and Pharmacologic Differences of CDK4\/6 Inhibitors in Breast Cancer","volume":"11","author":"George","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_34","first-page":"901","article-title":"Mechanisms of the CDK4\/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review)","volume":"39","author":"Liu","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/ijc.31220","article-title":"Palbociclib synergizes with BRAF and MEK inhibitors in treatment na\u00efve melanoma but not after the development of BRAF inhibitor resistance","volume":"142","author":"Martin","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1038\/s41598-022-09592-0","article-title":"Novel therapeutic strategy for melanoma based on albendazole and the CDK4\/6 inhibitor palbociclib","volume":"12","author":"Zhu","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2009-03-211466","article-title":"Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells","volume":"116","author":"Tanaka","year":"2010","journal-title":"Blood"},{"key":"ref_38","first-page":"2211","article-title":"AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B","volume":"44","author":"Takeda","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-10-3012","article-title":"Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide","volume":"17","author":"Santo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2010.08175.x","article-title":"AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders","volume":"150","author":"Dawson","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"18177","DOI":"10.1074\/jbc.M600064200","article-title":"Activated Jak2 with the V617F point mutation promotes G1\/S phase transition","volume":"281","author":"Walz","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","article-title":"The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","volume":"22","author":"Pophali","year":"2016","journal-title":"Cancer J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: A novel, selective tyrosine kinase inhibitor","volume":"38","author":"Blay","year":"2011","journal-title":"Semin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/cncr.21299","article-title":"AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells","volume":"104","author":"Verstovsek","year":"2005","journal-title":"Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1080\/10428190701385181","article-title":"The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell lines","volume":"48","author":"Chow","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acsmedchemlett.3c00019","article-title":"Synthesis of Artesunic Acid-Coumarin Hybrids as Potential Antimelanoma Agents","volume":"14","author":"Zippilli","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e4473","DOI":"10.7717\/peerj.4473","article-title":"pcr: An R package for quality assessment, analysis and testing of qPCR data","volume":"6","author":"Ahmed","year":"2018","journal-title":"PeerJ"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2956\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:08:42Z","timestamp":1760105322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25052956"],"URL":"https:\/\/doi.org\/10.3390\/ijms25052956","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,3]]}}}